AbbVie’s Q2 2024 net earnings drop to $1.37bn
The company reported a slight revenue increase to $14.46bn in the second quarter.
26 July 2024
26 July 2024
The company reported a slight revenue increase to $14.46bn in the second quarter.
Sales for the first half of the year rose by 5% CER, driven by demand for medicines and diagnostics.
BSV’s branded product portfolio spans women's health, fertility and critical care.
The approval is based on data from the Phase III BENEGENE-2 clinical trial of DURVEQTIX.
Ipsen will pay $111m in cash and equity upfront to gain the global rights, excluding the US, to Day One’s paediatric glioma therapy, Ojemda.
Sandoz launched the biosimilar of J&J’s Stelara in Europe in partnership with Samsung Bioepis to treat psoriasis and Crohn’s disease.
JNJ-2056 is being investigated in the Phase IIb ReTain study which enrols participants who are yet to show Alzheimer’s symptoms.
A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.